According to the Health Director-General, Dr Noor Hisham Abdullah, the Sinovac vaccine has yet to get the National Pharmaceutical Regulatory Agency’s (NPRA) nod during a virtual engagement session between the Health Ministry (MOH) and the media yesterday [Feb 26].
The vaccine is secured via a cooperation between Pharmaniaga and, Chinese pharmaceutical company, Sinovac Life Sciences Co Ltd and would involve a “fill and finish” process, in which the vials are filled and then packaged for distribution in Malaysia.
“We will need to look at the efficacy and the stability as well as other factors of the vaccines in our country,” the Health Director-General said.
“To date, Pharmaniaga has submitted two applications to NPRA, consisting of product registration for ready to be administered vials from Sinovac Life Sciences and for the fill and finish (F&F) that will be manufactured in our EU certified PLS plant,” Pharmaniaga Group Managing Director, Zulkarnain Md Eusope said.
The process is part of the registration in the application requirement by the National Pharmaceutical Regulatory Agency (NPRA).
The storage and distribution condition of this vaccine is between 2 to 8 degrees and proven to be very reliable and dependable as the technology was established more than 40 years ago.
The vaccine is also ready to use and requires no dilution.
The vaccines would be delivered via a special MASkargo flight and has arrived at the Kuala Lumpur International Airport (KLIA) at today [Feb 27].
The Sinovac vaccine is part of the National Covid-19 Immunisation Programme which is set to vaccinate 80 percent of Malaysians by the end of this year.